Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Proposed [GID-TA10723] Expected publication date: TBC
Search results
623 results
-
-
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]
Proposed [GID-TA10725] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Proposed [GID-TA10726] Expected publication date: TBC
-
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Proposed [GID-TA10431] Expected publication date: TBC
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
Proposed [GID-TA10632] Expected publication date: TBC
-
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Proposed [GID-TA10574] Expected publication date: TBC
-
Sotagliflozin for treating type 2 diabetes [ID1657]
Proposed [GID-TA10665] Expected publication date: TBC
-
Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]
Proposed [GID-TA10332] Expected publication date: TBC
-
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154
Proposed [GID-TA10198] Expected publication date: TBC
-
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Proposed [GID-TA10336] Expected publication date: TBC
-
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)
Proposed [GID-TA10426] Expected publication date: TBC
-
Voxelotor for treating sickle cell disease [ID1403]
Proposed [GID-TA10505] Expected publication date: TBC
-
Semaglutide for treating type 2 diabetes (ID1450)
Proposed [GID-TA10438] Expected publication date: TBC
-
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]
Proposed [GID-TA10297] Expected publication date: TBC
-
Pegvaliase for treating phenylketonuria [ID1110]
Proposed [GID-TA10345] Expected publication date: TBC
-
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)
Proposed [GID-TA10239] Expected publication date: TBC
-
Rivaroxaban for treating chronic heart failure [ID1462]
Proposed [GID-TA10393] Expected publication date: TBC
-
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Proposed [GID-TA10715] Expected publication date: TBC
-
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Proposed [GID-TA10717] Expected publication date: TBC
-
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]
Proposed [GID-TA10718] Expected publication date: TBC
-
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]
Proposed [GID-TA10719] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]
Proposed [GID-TA10707] Expected publication date: TBC
-
Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]
Proposed [GID-TA10709] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Proposed [GID-TA10748] Expected publication date: TBC
-
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]
Proposed [GID-TA10749] Expected publication date: TBC
-
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Proposed [GID-TA10750] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]
Proposed [GID-TA10751] Expected publication date: TBC
-
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Proposed [GID-TA10752] Expected publication date: TBC
-
Melphalan flufenamide for Multiple myeloma in Relapsing or refractory In combination with dexamethasone [ID3862]
Proposed [GID-TA10744] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Proposed [GID-TA10745] Expected publication date: TBC
-
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]
Proposed [GID-TA10746] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Proposed [GID-TA10747] Expected publication date: TBC
-
Bulevirtide for treating chronic hepatitis D [ID3732]
Proposed [GID-TA10652] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously treated EGFR-positive metastatic non-small-cell lung cancer [ID3873]
Proposed [GID-TA10766] Expected publication date: TBC
-
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]
Proposed [GID-TA10767] Expected publication date: TBC
-
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]
Proposed [GID-TA10768] Expected publication date: TBC
-
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]
Proposed [GID-TA10770] Expected publication date: TBC
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
Proposed [GID-TA10771] Expected publication date: TBC
-
Foscarbidopa–foslevodopa for treating motor fluctuations in Parkinson's disease [ID3876]
Proposed [GID-TA10772] Expected publication date: TBC
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Proposed [GID-TA10773] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
Proposed [GID-TA10775] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Proposed [GID-TA10776] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Proposed [GID-TA10778] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Proposed [GID-TA10779] Expected publication date: TBC
-
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]
Proposed [GID-TA10600] Expected publication date: TBC
-
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]
Proposed [GID-TA10737] Expected publication date: TBC
-
Avatrombopag for treating chronic immune thrombocytopenia [ID3838]
Proposed [GID-TA10738] Expected publication date: TBC
-
Ozanimod for treating moderate to severe ulcerative colitis [ID3841]
Proposed [GID-TA10732] Expected publication date: TBC